Caliway Biopharmaceuticals (TWSE: 6919) reported that its CBL-514 injection produced a 3.1-point mean drop in lipoma pain scores at Week 20 of a Phase 2 Dercum's disease study, against 1.9 points for placebo, a difference significant at p=0.005.
The randomized, single-blind, placebo-controlled CBL-0202DD trial enrolled patients with Dercum's disease, a rare disorder in which subcutaneous adipose tissue accumulates into painful lipomas. Final statistical results, announced September 21 and released publicly the following day, showed the primary efficacy endpoint met in both the Full Analysis Set and the Per-Protocol population. In the PP population, the same 3.1-point reduction compared against 1.4 points for placebo, at p=0.0002.
"The magnitude of response continued to increase over time, supporting the durability of the treatment effect," the company said in the release, adding that no drug-related serious adverse events were reported.
Secondary endpoints reinforced the primary result. At Week 16, CBL-514 patients recorded a mean 3.5-point pain reduction versus 1.7 points for placebo (p=0.0017); at Week 24, the gap widened to 4.1 points versus 1.7 points (p<0.0001). The PP population showed the same trajectory — 3.5 points versus 1.2 points at Week 16 (p=0.0001) and 4.1 points versus 1.2 points at Week 24 (p<0.0001). Because the benefit grew across successive assessment points rather than plateauing, the data support a cumulative effect from repeat dosing rather than a transient response.
An exploratory analysis found roughly 90% of CBL-514-treated patients achieved a clinically meaningful reduction of at least 3 points in more than half of their treated painful lipomas, compared with a markedly lower rate on placebo. Safety was consistent with prior studies: the most common treatment-emergent events were mild-to-moderate local injection-site reactions, and no drug-related serious adverse events occurred.
CBL-514 is a first-in-class small-molecule injection designed to selectively induce adipocyte apoptosis — programmed cell death in fat cells — at the injection site without causing necrosis or damaging surrounding tissue. A separate formulation, CBL-514D, is designated for Dercum's disease. Caliway has now run 10 completed trials with finalized statistical reports across more than 544 subjects, and the company says all primary and key secondary efficacy endpoints have been met.
The commercial case rests on an empty competitive field. No therapy is approved specifically for Dercum's disease, and current options such as surgical removal provide only temporary relief. Market research cited by Caliway put the global Dercum's disease market at about $11.3 billion in 2021, projected to reach roughly $19.96 billion by 2030, a compound annual growth rate of about 6.76%.
Caliway said several key opinion leaders and potential pharmaceutical partners have flagged CBL-514's potential in lipedema, a chronic condition affecting roughly 10% of women worldwide that shares clinical features with Dercum's disease. The company estimates that market opportunity exceeds $30 billion, with no approved curative therapies and weight loss alone failing to address the underlying fat accumulation. Caliway plans to work with clinical experts to assess feasibility and development strategy for the indication.
For holders, the readout shifts the central question from whether CBL-514 works in Dercum's disease to how quickly it can be filed. The company has not yet disclosed a Phase 3 design, enrollment target, or regulatory submission timeline for CBL-514D, and no partnership or licensing terms have been announced. Those three disclosures — trial design, filing path under the 505(b)(1) route, and any partner commitment — are the next checkpoints that determine whether the Phase 2 result converts into a commercial asset.
This article is for informational purposes only and does not constitute investment advice.
